Phase II trial of ISIS 353512.
Phase of Trial: Phase II
Latest Information Update: 06 May 2011
At a glance
- Drugs ISIS 353512 (Primary)
- Indications Cancer; Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Ionis Pharmaceuticals
- 06 May 2011 Isis Pharmaceuticals has reported that it is ready to initiate this trial.
- 25 Feb 2011 New trial record